Alnylam Says Estimates of Damages in Tekmira Suit Could Reach $1.5B | GenomeWeb

Alnylam Pharmaceuticals this week disclosed that a jury trial for its trade secret litigation with Tekmira Pharmaceuticals is expected to begin Nov. 14.

In the disclosure, which was made concurrent with the Alnylam's release of its third-quarter financial results, the RNAi drug shop noted that its 2012 financial guidance of roughly $280 million in year-end cash, cash equivalents, and marketable securities does not include the impact of payments that could be made in connection with the resolution of the litigation.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.